

Sabouraud Dextrose Agar - Instructions for Use

Intended Use

BACGro™ Sabouraud Dextrose Agar (SDA), when prepared as directed, is intended for use for the culture and isolation of yeasts and molds. Sabouraud Dextrose Agar is not intended for use in diagnosis, treatment, or prevention of disease in humans. BACGro™ Sabouraud Dextrose Agar conforms to harmonized USP/EP/JP requirements¹⁻³.

Product Summary

Sabouraud Dextrose Agar is a general-purpose medium used for the cultivation and isolation of a wide variety of yeasts and molds. The low pH promotes growth of these fungi while simultaneously being slightly inhibitory to competing bacteria that may be present in a sample. Further selectivity can be achieved through the addition of antibiotic supplements.

The media includes peptone to provide nitrogen and vitamins for the yeast and mold. Dextrose is included at a very high concentration to provide a carbon source for energy. Agar serves as the solidifying agent.

Formulation (per Liter)*

Peptone	10.0 g
Dextrose	40.0 g
<u>Agar</u>	<u>15.0 g</u>
Total	65.0 g/L

*Formula may be supplemented and/or adjusted as required to meet performance criteria

Note: Sabouraud Dextrose Agar with Chloramphenicol is also available, containing chloramphenicol at 100mg per Liter

Directions

1. Add 65.0 g of Sabouraud Dextrose Agar powder to 1L purified water.
2. Heat and agitate to form aqueous solution.
3. Autoclave at 121 degrees Celsius for 15 minutes.
4. Cool prior to use.

Precautions

This product is for laboratory use only and should only be used by qualified, trained laboratory personnel. Personnel should always use proper aseptic technique and observe all biohazardous precautions. All microbiological cultures should be presumed to be infectious.

Avoid ingestion, inhalation, or contact with skin and mucous membranes. If contact occurs, flush the area with clean water.

Quality Control Specifications

Gold Standard Diagnostics tests each lot of manufactured BACGro™ culture media utilizing appropriate control organisms and specifications as documented on the Certificate of Analysis. End users should perform quality control testing in accordance with government regulatory requirements and accreditation guidelines. The following specifications are routinely used for testing:

Appearance (dehydrated): Light beige, homogenous, free flowing powder, free of debris

Appearance (prepared): Clear to hazy, amber, with no precipitate or debris

pH (prepared): 5.4 – 5.8 at 25°C

Organism Performance:

Strain ID			
	Time	Temp.	Result
<i>Aspergillus niger</i> (ATCC® 16404)	2 – 5 days	25° C	Growth
<i>Candida albicans</i> (ATCC® 10231)	2 – 5 days	25° C	Growth
<i>Saccharomyces cerevisiae</i> (ATCC® 9763)	2 – 5 days	25° C	Growth
<i>Trichophyton mentagrophytes</i> (ATCC® 9533)	2 – 5 days	25° C	Growth

Limitations of the Procedure

This product is not labeled for use as a medical device, and is not intended to diagnose, treat, or prevent disease.

Due to variation in nutritional requirements, some strains may be encountered that grow poorly in this medium.

Antimicrobial agents that are added to a medium may inhibit the growth of fungal pathogens.

Acidic media should avoid being overheated; this will result in a softer medium

Storage and Expiration

BACGro™ Sabouraud Dextrose Agar should be stored at 2 – 30 degrees Celsius. Because of the hygroscopic nature of dehydrated culture media, it should be stored in a dry place and the lid should remain tightly sealed. Media should be discarded if it is not free flowing or shows discoloration.

The expiration date printed on the label is applicable to media stored as directed.

Catalog Numbers

DCM3701 – Sabouraud Dextrose Agar, 500g

DCM3705 – Sabouraud Dextrose Agar, 5kg

DCM3710 – Sabouraud Dextrose Agar, 10kg

DCM3805 – Sabouraud Dextrose Agar with Chloramphenicol, 5kg

DCM3810 – Sabouraud Dextrose Agar with Chloramphenicol, 10kg

¹ United States Pharmacopoeial Convention. *United States Pharmacopoeia and National Formulary (USP-NF)*.

² Directorate for the Quality of Medicines and the Council of Europe. *The European Pharmacopoeia*.

³ Pharmaceuticals and Medical Devices Agency, Ministry of Health, Labor, and Welfare. *Japanese Pharmacopoeia*.

Revision History:

Revision	Description	Effective Date
04	Changed incubation time from "2 – 7 days" to "2 – 5 days" to match industry standard.	13-MAR-2024
03	Added part number DCM3705	23-AUG-2023
02	Added part number DCM3710	13-APR-2021
01	Document creation	19-OCT-2019